Introduction: The presence of left ventricular hypertrophy (LVH) in patients with Chronic Kidney Disease (CKD) is associated with worsening
Introduction
Chronic Kidney Disease (CKD) is a worldwide public health challenge with adverse outcomes of kidney failure, cardiovascular disease and premature death [1] . CKD patients are at significantly increased risk for both morbidity and mortality from cardiovascular disease [2, 3] .
In fact cardiovascular disease (CVD) is the leading cause of death in CKD populations in the developed world [2] . The situation is no different in developing countries like Ghana. Eghan and colleagues [4] reported CVD as responsible for 40% of deaths among a dialysis cohort. Traditional CVD risk factors such as hypertension, diabetes mellitus, smoking, and dyslipidaemia are common in individuals with CKD than those with normal renal function [5] [6] [7] [8] . Other nontraditional or uraemia related CVD risk factors-anaemia, C reactive protein, carotid intima -media thickness and asymmetric dimethyl arginine have been identified among patients with CKD [5, 9] . Left ventricular hypertrophy (LVH) has been reported as a prevalent cardiovascular complication among CKD patients. The presence of LVH in CKD patients generally portends a negative prognostic value because it can contribute to the development of heart failure, ischaemic heart disease, arrhythmias and sudden death. LVH is a strong predictor of cardiovascular morbidity and mortality among CKD patients [10] . Several modalities exist for the assessment of LVH. Compared to electrocardiography [11] [12] [13] [14] , echocardiography [15, 16] , computed tomography, and magnetic resonance imaging [17] have been used to provide more accurate assessments of myocardial mass. However, electrocardiograms are more convenient and less expensive compared to the other imaging modalities.
Several electrocardiographic left ventricular hypertrophy (ECG LVH) criteria exist. However, the standard voltage criterion reported by Sokolow and Lyon [18] remains the most widely used. LVH determined by this criterion is independently associated with echocardiographic LVH, and cardiovascular morbidity and mortality [19] . Regression of ECG LVH is also associated with reduction in adverse cardiovascular outcomes [20] . Among Ghanaian CKD patients however, the prevalence of this important CVD risk factor is not known. We set out to examine the prevalence and determinants of LVH among CKD patients during their initial assessment at a tertiary hospital adult renal service.
Methods
This was a cross sectional study carried out over a 1-year period at the Komfo Anokye Teaching Hospital (KATH). KATH is the second largest hospital in Ghana and caters for patients in middle and northern zones of the country. The hospital provides clinical services for both adult and paediatric renal patients. Haemodialysis is the main mode of Renal Replacement Therapy (RRT). Chronic Kidney Disease (CKD) patients attending the renal clinic over a 1 year period were eligible for inclusion in the study. Consecutive patients diagnosed with CKD based on the case definition age 18 years and above were eligible for inclusion. Eligible patients were not to be undergoing dialysis. Patients attending the renal clinic with diagnosis other than CKD and CKD patients who did not provide informed consent were excluded from this study. The abdominopelvic ultrasound results are represented in Table 2 .
The commonest sonographic finding in our cohort was reduced renal sizes and was present in 38.9% of cases. Thirty three percent of patients had reduced renal sizes with loss of corticomedullary differentiation. Two patients had polycystic kidney disease while 6.9% had normal sonographic findings ( Table 2 ).
The analysis of association between LVH and risk factors is presented in Table 3 
Discussion
The mean age of study participants was 43.9 ± 17.8 years. This is in agreement with other published studies that found CKD to be commoner in the third to fifth decades of life [4, 21] . There was a preponderance of males (M/F = 1 . On the other hand, the development of CKD is a cause of secondary hypertension and can worsen preexisting hypertension increasing the incidence of resistant hypertension [28] . Hypertension as a CKD complication is an important risk factor for left ventricular hypertrophy. It is therefore essential to adequately treat hypertension to forestall the decline in GFR and limit its impact on the development of LVH that results from poor blood pressure control. High blood pressure remains a major challenge to health care systems in both developed and developing countries [23] . The scale of the problem mandates investment in primary and secondary healthcare as well as patient education.
It is also important to emphasise utilisation of antihypertensive agents that can result in regression or even prevent development of
LVH. Attainment of LVH regression is desirable as it reduces adverse
Page number not for citation purposes 5 outcomes like cardiac arrhythmias and sudden death [29, 30] . Left ventricular hypertrophy was associated with both high systolic and diastolic blood pressures. This is in agreement with other published data [11, 22, 23, 31] . There were gender differences in the prevalence of LVH as the majority of respondents were males; this is in accord with findings from other studies [14] . This may be due to gender differences in body size as left ventricular mass is a function of body size. In the present study increased body mass index was significantly associated with LVH (OR 1.9 CI 1.4-3.7, p = 0.04). The finding that male gender is a determinant of LVH is similar to the findings from studies from developing [14, 16] and developed countries [17] . There was no association between anaemia and LVH. This is in contrast to the findings of Chijioke et al [13] and other studies from the western world [11, 21, 32] in which anaemia has been found to be a determinant of LVH. Proteinuria was not associated with LVH in this study. There appears not to be a consistent association between the LVH and proteinuria; while some studies [32, 33] report proteinuria to be a determinant of LVH, other studies found no such association [17] . Indeed McQuarie et al [17] reported that the association between LVH and proteinuria is lost in patients with stage 3-5 CKD. Our study population comprised exclusively stage 3-5 patients and this probably accounts for the similar findings in the present study.
No echocardiographic assessment of LVH was done in our study, so we were unable to determine the diagnostic test performance of ECG LVH in this population. Although our sample size was moderately large, we may have missed relationships that may have been significant if the strength of the relationship was not high.
Finally, ambulatory Blood pressure monitoring would have been a preferred means of confirming high blood pressure.
Conclusion
In conclusion, there is a high prevalence of left ventricular hypertrophy among CKD patients in Kumasi, Ghana. High diastolic blood pressure, high pulse pressure and increased BMI as well as male gender were found to be significantly associated with the presence of LVH in this cohort. Adequate control of blood pressure is important to forestall the development of CKD and other end organ damage. Early detection of LVH and interventions aimed at prevention and/or regression of LVH are to be encouraged.
What is known about this topic
 CKD patients are at significantly increased risk for both morbidity and mortality from cardiovascular disease;
 There is data from the developed world on the incidence of left ventricular hypertrophy and its impact on cardiovascular outcomes in CKD patients.
What this study adds
 To the best of our knowledge, this study is the first report of the high burden of LVH in Ghanaian CKD patients;
 Our study found pulse pressure, high DBP, increased BMI and male gender to be significant associated factors of LVH in our Ghanaian CKD cohort.
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